Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Discovery
Cancer Discovery
  • Home
  • About
    • The Journal
    • AACR Journals
    • Journal Sections
    • Subscriptions
    • Reviewing
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Collections
      • COVID-19 & Cancer Resource Center
      • Clinical Trials
      • Immuno-oncology
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
    • Journal Press Releases
  • COVID-19
  • Webinars
  • 10th Anniversary
  • Search More

    Advanced Search

Research Watch

A Novel ALK Isoform Arises via Alternative Transcription Initiation

DOI: 10.1158/2159-8290.CD-RW2015-197 Published December 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading
  • Major finding: Alternative transcription initiation results in a novel ALK transcript, ALKATI, in melanomas.

  • Clinical relevance: ALK inhibitors suppress ALKATI activity and may benefit patients with ALKATI-expressing tumors.

  • Impact: These results define a previously uncharacterized mechanism for oncogene activation in cancer.

Figure1

Oncogenes have been shown to be activated by various genetic alterations, including mutations, translocations, and amplifications. However, whether oncogenes can also be activated by other mechanisms remains unclear. To address this question, Wiesner and colleagues used RNA sequencing to identify differential expression of exons encoding the kinase domains of receptor tyrosine kinases in metastatic melanoma and thyroid carcinoma. This analysis revealed a previously uncharacterized transcript of anaplastic lymphoma kinase (ALK) consisting of a fragment of intron 19 followed by exons 20–29 that resulted from alternative transcription initiation (ATI) via an active ATI site in intron 19. Analysis of tumor samples from The Cancer Genome Atlas indicated that this ALK isoform, referred to as ALKATI, was expressed in approximately 11% of melanomas and sporadically in other cancers, but not in normal tissues. Comprehensive genetic studies showed that ALKATI was expressed from both ALK alleles, independent of genomic aberrations at the ALK locus. Transcriptional activation of the ALKATI isoform resulted in expression of three distinct proteins, each of which contained the intact ALK intracellular tyrosine kinase domain but lacked the extracellular and transmembrane domains. These ALKATI proteins were activated via homodimerization and autophosphorylation and localized to both the nucleus and cytoplasm, in contrast to other ALK mutants that localized primarily to the cytoplasm. Expression of ALKATI was sufficient to induce growth factor–independent proliferation in vitro and promoted tumor growth in vivo, consistent with an oncogenic function. Pharmacologic ALK inhibitors such as crizotinib suppressed ALKATI phosphorylation and signaling and triggered regression of ALKATI-driven tumors. Furthermore, crizotinib treatment led to rapid tumor shrinkage and symptomatic improvement in a patient with ALKATI-expressing metastatic melanoma. These findings suggest an alternative mechanism for oncogene activation in cancer and support the notion that ALK inhibitors may be beneficial in patients with ALKATI-driven tumors.

Wiesner T, Lee W, Obenauf AC, Ran L, Murali R, Zhang QF, et al. Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. Nature 2015;526:453–7.

Notes

Note: Research Watch is written by Cancer Discovery editorial staff. Readers are encouraged to consult the original articles for full details. For more Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/content/early/by/section.

  • ©2015 American Association for Cancer Research.
PreviousNext
Back to top
Cancer Discovery: 5 (12)
December 2015
Volume 5, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Discovery article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
A Novel ALK Isoform Arises via Alternative Transcription Initiation
(Your Name) has forwarded a page to you from Cancer Discovery
(Your Name) thought you would be interested in this article in Cancer Discovery.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
A Novel ALK Isoform Arises via Alternative Transcription Initiation
Cancer Discov December 1 2015 (5) (12) 1233; DOI: 10.1158/2159-8290.CD-RW2015-197

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
A Novel ALK Isoform Arises via Alternative Transcription Initiation
Cancer Discov December 1 2015 (5) (12) 1233; DOI: 10.1158/2159-8290.CD-RW2015-197
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Notes
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

Research Watch

  • IL12Rβ1 Partial Agonists Are Active with Reduced Toxicity In Vivo
  • Inhibitory CD161 Receptor Is Expressed on Glioma-Infiltrating T Cells
  • Combination Immune Checkpoint Blockade Promising in Operable NSCLC
Show more Research Watch

Oncogenes

  • The Leukemia-Driving Fusion Protein TCF3–HLF Is Regulated by EP300
  • Transposable Elements Regulate Oncogene Expression in Human Cancers
  • KRASG12D Promotes Immunosuppression in Colorectal Cancer
Show more Oncogenes
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • OnlineFirst
  • Current Issue
  • Past Issues

Info For

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Discovery

  • About the Journal
  • Editors
  • Journal Sections
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Discovery
eISSN: 2159-8290
ISSN: 2159-8274

Advertisement